Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking.
about
Medical versus surgical treatment for refractory or recurrent peptic ulcerMedical versus surgical treatment for refractory or recurrent peptic ulcerTime dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approachLate surgical complications after gastric by-pass: a literature reviewThe changing face of pathogen discovery and surveillanceRisk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study InvestigatorsPrevalence of non-Helicobacter pylori duodenal ulcer in Karachi, PakistanA nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug useH pylori infection and other risk factors associated with peptic ulcers in Turkish patients: a retrospective studyRisk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.Host Determinants of Expression of the Helicobacter pylori BabA Adhesin.Is Helicobacter pylori the primary cause of duodenal ulceration?Reliability of Helicobacter pylori and CagA serological assaysDiagnosis and treatment of perforated or bleeding peptic ulcers: 2013 WSES position paper.A role for the vacuolating cytotoxin, VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach.The burden of smoking in Israel-attributable mortality and costs (2014).Effect of rabeprazole on the transport and distribution of levofloxacin in rat stomachsIntravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs.Gastroprotective Effect of Ginger Rhizome (Zingiber officinale) Extract: Role of Gallic Acid and Cinnamic Acid in H(+), K(+)-ATPase/H. pylori Inhibition and Anti-Oxidative Mechanism.Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pyloriRepeat upper gastrointestinal endoscopy in patients with functional dyspepsia: yield, findings, and predictors of positive findingsSignificant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction.Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease.Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults.Management of dyspepsia at the beginning of the twenty-first century.Substance use after bariatric surgery: A review.Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer DiseasesSerum positive cagA in patients with non-ulcer dyspepsia and peptic ulcer disease from two centers in different regions of Turkey.Perceived stress as a risk factor for peptic ulcers: a register-based cohort studyUse of serum-specific immunoglobulins A and G for detection of Helicobacter pylori infection in patients with chronic gastritis by immunoblot analysis.Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality.Clinical application of pharmacogenetics in gastrointestinal diseases.Precise role of H pylori in duodenal ulceration.Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin.Toxicity of Smokeless Tobacco Extract after 184-Day Repeated Oral Administration in RatsExpression of the Helicobacter pylori virulence factor vacuolating cytotoxin A (vacA) is influenced by a potential stem-loop structure in the 5' untranslated region of the transcript.Long-term risk of gastrointestinal cancers in persons with gastric or duodenal ulcers.Seroprevalence of anti-Hp and anti-cagA antibodies among healthy persons in Golestan province, northeast of Iran (2010)
P2860
Q24186004-3085ACC0-87BB-4ED3-BA9F-1AA6F1A26FD5Q24186307-1E1999E1-0E3F-49BC-A7C2-DF542C55F701Q24673561-94B85AF2-2585-4D15-A377-33EC34A7021BQ26801486-CDEB73DA-6E79-4624-A2F5-0829A85D2E3EQ27008860-742F21C0-B459-48B0-9430-02D25F32EEA7Q28176186-6ACE9BD1-FBA6-4B73-891C-7829BD8A40E0Q28180899-B4736A09-C549-4FB2-9B4C-498F00ED36B4Q28186337-00E9D601-07A1-423A-94F8-4A5644A9C399Q28217588-17CF65C4-3943-4D85-B668-CEC7C4CB3901Q33185503-BCA058EA-6DB8-4A17-A236-8D3EF5FCFD68Q33572489-AF2014B9-FDA8-4920-AC8F-0D08D63E12D3Q33780521-AF85E332-3941-47E6-AC3E-0352E0EAFCDDQ33942839-B5CE52A6-0BA7-4668-A4E5-A4E752F1E1A3Q34024765-0EC851AA-D6B2-4587-91DC-8CC442DAE258Q34061670-0B279B69-A075-4D1B-A21E-8BA7F8AF6CB1Q34182516-0155882C-D87C-4A83-839F-E17CC1419258Q34444010-0DAF82ED-666B-406D-98D5-9336E5F011A0Q34735634-82578574-41F6-4575-AFCE-242DDCA13075Q35030551-3DBC6334-0039-4F61-85B5-0E0BDEAC3BD4Q35105330-DC76DF32-51CD-414D-B975-B869648B3AB9Q35165868-858E224F-10DF-43E1-AEF6-9029DD5EF240Q35540796-D74AAE54-4416-4D6F-8E9B-6C4476FE34E7Q35567077-F9D7D20C-265B-4D67-898E-736EF94EEF3EQ35580087-B2F8AE65-7D38-4545-97D4-890E4BCFF523Q35598340-0BADAB54-FB80-48CA-A6BC-21B81F57CAB2Q35600513-9A786C6F-F35D-4B15-B01E-D1532C04C9E5Q35922229-BA426303-12FC-47ED-A242-6D47B274D74AQ36158848-33E46021-F5CC-4056-B93F-64E4AF4410DFQ36169259-5A635A22-0AD2-42FC-B30B-2480532EC773Q36178725-62E369BB-35A7-49FF-8CA6-2D0FE9117F0AQ36205934-BA357713-029E-40B4-BA3C-7A4A6C21D32EQ36547893-7F29D8C1-9DD5-4AE5-A62E-7461BFC40EB6Q36561643-CC4EE103-E15E-452F-AB3A-E8CF0CB600E1Q36613862-45EB7DF0-0828-4764-B074-868B96BF2FE1Q36638190-9AACFBCC-C9D9-46B5-A699-C7FF3EECB7A9Q36715136-8829246E-4453-47D9-AB5F-A5A99825778FQ36732361-A220978D-86E9-494D-B9D1-C2490EEBEACFQ36832763-D5FDB674-F51A-4490-9A78-AC15C430E654Q37045624-0C83D253-37AF-41BF-9929-AEEFAA052FAFQ37164153-AA08E815-5B88-48DA-90A0-CB010297657F
P2860
Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@ast
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@en
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@nl
type
label
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@ast
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@en
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@nl
prefLabel
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@ast
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@en
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@nl
P1476
Meta-analysis of risk factors ...... icobacter pylori, and smoking.
@en
P2093
P356
10.1097/00004836-199701000-00002
P577
1997-01-01T00:00:00Z